Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-05-24 DOI:10.1080/14737140.2023.2213892

Kanchi Patell, Matthew Kurian, Jorge A Garcia, Prateek Mendiratta, Pedro C Barata, Angela Y Jia, Daniel E Spratt, Jason R Brown

{"title":"Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.","authors":"Kanchi Patell, Matthew Kurian, Jorge A Garcia, Prateek Mendiratta, Pedro C Barata, Angela Y Jia, Daniel E Spratt, Jason R Brown","doi":"10.1080/14737140.2023.2213892","DOIUrl":null,"url":null,"abstract":"Introduction: Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment alone. Despite the advent of novel anti-androgen medications, many patients continue to progress, and as a result, there is a growing need for additional treatment options.Areas covered: Lutetium-177 (177Lu) - PSMA-617 has become one of the new frontline treatment options for refractory metastatic castrate resistant prostate cancer after the failure of novel anti-androgen therapy and chemotherapy. Lu-177 has been used in real-world prospective trials and is now becoming utilized in newer phase III clinical trials. Here, we present a comprehensive overview of the current literature, covering retrospective studies, prospective studies, and clinical trials that established Lutetium-177-PSMA-617 (177Lu-PSMA-617) for the treatment of mCRPC.Expert opinion: 177Lu - PSMA-617 has been approved for treatment of mCRPC based on positive phase III studies. While this treatment is tolerable and effective, biomarkers are necessary to determine which patients will benefit. In the future, radioligand treatments will likely be utilized in earlier lines of therapy and potentially in combination with other prostate cancer treatments.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 7","pages":"731-744"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2213892","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment alone. Despite the advent of novel anti-androgen medications, many patients continue to progress, and as a result, there is a growing need for additional treatment options.

Areas covered: Lutetium-177 (¹⁷⁷Lu) - PSMA-617 has become one of the new frontline treatment options for refractory metastatic castrate resistant prostate cancer after the failure of novel anti-androgen therapy and chemotherapy. Lu-177 has been used in real-world prospective trials and is now becoming utilized in newer phase III clinical trials. Here, we present a comprehensive overview of the current literature, covering retrospective studies, prospective studies, and clinical trials that established Lutetium-177-PSMA-617 (¹⁷⁷Lu-PSMA-617) for the treatment of mCRPC.

Expert opinion: ¹⁷⁷Lu - PSMA-617 has been approved for treatment of mCRPC based on positive phase III studies. While this treatment is tolerable and effective, biomarkers are necessary to determine which patients will benefit. In the future, radioligand treatments will likely be utilized in earlier lines of therapy and potentially in combination with other prostate cancer treatments.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于治疗转移性阉割抵抗性前列腺癌的镥-177 PSMA：系统综述。

导言：转移性阉割耐药前列腺癌（mCPRC）仍是一种侵袭性前列腺癌，对传统的激素治疗已不再敏感。尽管出现了新型抗雄激素药物，但许多患者的病情仍在继续发展，因此，对其他治疗方案的需求日益增长：镥-177（177Lu）--PSMA-617已成为新型抗雄激素疗法和化疗失败后治疗难治性转移性阉割耐药前列腺癌的新一线治疗方案之一。Lu-177已被用于真实世界的前瞻性试验，目前正被用于较新的III期临床试验。在此，我们对目前的文献进行了全面的综述，涵盖了回顾性研究、前瞻性研究和临床试验，这些研究确定了镥-177-PSMA-617（177Lu-PSMA-617）用于治疗mCRPC。专家观点：基于积极的III期研究，177Lu-PSMA-617已被批准用于治疗mCRPC。虽然这种治疗方法耐受性好、疗效显著，但仍需要生物标志物来确定哪些患者将从中受益。未来，放射性配体治疗可能会被用于早期治疗，并有可能与其他前列腺癌治疗方法联合使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.